Wei-Qin (Tony) Tong, PhD is President of Austarpharma and CSO of Guangzhou Bostal Drug Delivery Co.
Prior to joining Austarpharma, Tong was Head of R&D for G&W labs for a year, responsible for company’s R&D and RA organizations; Vice President and Head of Development for Teva’s US R&D center located in Pomona, New York for eight years, responsible for the development of high-barriers-to-entry generic and 505b(2) new drugs; Executive Director, Pharmaceutical Development at Novartis for six years, responsible for all the formulation development activities of the US R&D center. Before Novartis, he spent 11 years with GlaxoSmithKline, progressing through positions of increasing scientific and managerial responsibilities. He has successfully contributed to the development of more than 30 marketed products including over 10 brand products and over 10 first-to-file generic products. Tong has published over 70 research papers, book chapters and presentations, and contributed to over 20 patents. His research publication on in situ salt screening received the AAPS Outstanding Manuscript Award.
Tong earned his PhD in Pharmaceutics from University of Iowa in 1991.